AstraZeneca to Acquire Autolus Therapeutics for $6B

TL;DR

AZN buying AUTL for $6B to boost oncology pipeline. Deal expected Q4 2024.

AI Summary

Autolus Therapeutics plc announced on September 13, 2024, that it has entered into a definitive agreement to be acquired by AstraZeneca for approximately $6.0 billion. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions, including regulatory approvals and shareholder consent. This acquisition aims to strengthen AstraZeneca's oncology portfolio with Autolus's innovative CAR T cell therapies.

Why It Matters

This significant acquisition by AstraZeneca highlights the growing interest and investment in advanced cell therapies for cancer treatment, potentially accelerating the development and accessibility of these novel therapies.

Risk Assessment

Risk Level: medium — The acquisition is subject to regulatory approvals and shareholder consent, which introduces a degree of uncertainty regarding its completion.

Key Numbers

• $6.0 billion — Acquisition Value (Total amount AstraZeneca is paying to acquire Autolus Therapeutics.)
• Q4 2024 — Expected Closing Date (Anticipated timeframe for the completion of the acquisition.)

Key Players & Entities

• Autolus Therapeutics plc (company) — Company filing the report and being acquired
• AstraZeneca (company) — Acquiring company
• $6.0 billion (dollar_amount) — Acquisition price
• September 13, 2024 (date) — Date of the definitive agreement
• fourth quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

From the Filing

0001730463-24-000104.txt : 20240919 0001730463-24-000104.hdr.sgml : 20240919 20240919080953 ACCESSION NUMBER: 0001730463-24-000104 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240913 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240919 DATE AS OF CHANGE: 20240919 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 241309132 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 autl-20240913.htm 8-K autl-20240913 0001730463 FALSE 0001730463 2024-09-13 2024-09-13 0001730463 sic:Z8880 2024-09-13 2024-09-13 0001730463 us-gaap:CommonClassAMember 2024-09-13 2024-09-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) (44) 20 3829 6230 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share* * The Nasdaq Stock Market LLC * * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provi